Clinical trial backs VirtualPhenotype test:
This article was originally published in Clinica
Virco says it now has the first evidence from a clinical trial to show that its VirtualPhenotype HIV drug resistance test is better than conventional genotyping tests at predicting the way HIV patients respond to therapy. The trial showed that the VirtualPhenotype test was a reliable and independent predictor of clinical outcome compared with a genotyping assay, which failed to predict outcome, reports the Cambridge, UK-based company. Virco's test involves combining the genetic information from a patient's virus with a large database of resistance information from previous virus samples to produce a resistance score for each drug.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.